Collagen Signalling and Hodgkin Lymphoma
Research type
Research Study
Full title
Impact of tumour expression of collagen and its receptors on outcome in patients with Hodgkin lymphoma
IRAS ID
204247
Contact name
Paul Murray
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Although many patients with Hodgkin lymphoma, a type of blood cancer, can expect to be cured, around 10-15% will die of their disease, and many who survive will experience significant side effects as a result of short-term and long-term side effects of treatment. In this research project we want to examine tissues from patients diagnosed with Hodgkin lymphoma to look for the presence of collagen, a component of normal scar tissue but which is also present in some cancers. We also want to look for other genes that are responsible for the production of collagen and those that respond to its presence in tumours. In particular, we think that the collagen present in Hodgkin lymphoma tissues might make them more resistant to the drugs doctors use to treat this form of cancer. This knowledge might help us to design better and less toxic treatments for people with Hodgkin lymphoma.
REC name
HSC REC A
REC reference
18/NI/0037
Date of REC Opinion
13 Feb 2018
REC opinion
Favourable Opinion